Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7-1 and interleukin-12

Human Gene Therapy
Eva PizzoferratoN L Berinstein

Abstract

The A20 murine B cell lymphoma was transfected with B7-1 and subsequently these variants and vector control variants were retrovirally infected to express murine interleukin-12 (mIL-12). In vitro data showed that the B7-1 variants enhanced secretion of IL-2 and IL-4 by allogeneic T cells in mixed lymphocyte tumor cultures. While IL-12 variants stimulated IFN-gamma, variants expressing both B7-1 and IL-12 stimulated IFN-gamma, IL-2, and IL-4 secretion. Tumorigenicity experiments showed that whereas B7-1 delayed tumor onset, only the mIL-12 variants with or without B7-1 were completely rejected in syngeneic hosts. In addition, tumor-free mice were protected against subsequent challenge with the parental unmodified cells and had enhanced cytotoxic T lymphocyte (CTL) lysis activity. Results from minimal disease mixing experiments demonstrated that only the A20/B7-1/mIL-12 variant was able to reject A20 unmodified cells inoculated at the same site, whereas prolonged survival was observed when the A20 parental cells were inoculated at different sites. Depletion studies and injections into nu-/nu- mice demonstrated that both CD4+ and CD8+ T cells may mediate immunity. These data suggest that vaccinations with tumor cells genetically m...Continue Reading

References

Aug 1, 1992·Cellular Immunology·M K GatelyR Chizzonite
Oct 1, 1992·The Journal of Experimental Medicine·R G HawleyT S Hawley
Dec 15, 1991·Journal of Immunological Methods·P Matzinger
Feb 1, 1989·European Journal of Immunology·S R CardingK Bottomly
Oct 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·A A Brian, H M McConnell
Dec 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·T H WattsH M McConnell
Nov 10, 1995·Science·J Cohen
Feb 1, 1994·The Journal of Experimental Medicine·L ChenK E Hellström
Nov 1, 1995·The Journal of Experimental Medicine·T C WuD M Pardoll
Jul 14, 1995·Cell·N K Nanda, E E Sercarz
Jan 1, 1995·Annual Review of Immunology·D M Pardoll
Oct 1, 1993·Current Opinion in Immunology·D M Pardoll
Oct 1, 1994·Current Opinion in Immunology·S Ostrand-Rosenberg
Oct 1, 1993·The Journal of Experimental Medicine·M J BrundaM K Gately

❮ Previous
Next ❯

Citations

Aug 5, 2004·Current Oncology Reports·Renier J Brentjens
Apr 1, 2004·International Journal of Cancer. Journal International Du Cancer·Eva Pizzoferrato
Mar 26, 2015·Immunotherapy·Robyn Aa OldhamJeffrey A Medin
Feb 13, 2001·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Y X XuS C Gautam
Apr 21, 1999·International Journal of Cancer. Journal International Du Cancer·S HallezO Leo
Apr 15, 2018·Leukemia·Michael C Milone, Una O'Doherty
May 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kutlu G ElpekHaval Shirwan
Jun 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pierre L TriozziRobert M Conry

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.